相关实验视频

Updated: Apr 28, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

结合R-GDP的Selinexor作为复发性/耐药性扩散性大B细胞淋巴瘤的救援疗法

Shiyu Jiang^1,2, Youli Li^1,3, Chuanxu Liu^1,2

¹Department of Medical Oncology, Fudan University Shanghai Cancer Center Shanghai 200032, China.

American journal of cancer research

|January 12, 2026

概括

结合R-GDP的Selinexor在复发或耐火性扩散大B细胞淋巴瘤 (R/R DLBCL) 中表现出适度的疗效. 随后使用自身干细胞移植 (ASCT) 或CAR-T细胞的治疗显著改善了生存结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

复发性或耐火性扩散性大B细胞淋巴瘤 (R/R DLBCL) 是一个严重的治疗挑战,预后不佳.
选择性核出口抑制剂 (XPO1) Selinexor在R/R DLBCL中表现出潜在的活性.
优化二线治疗策略对于改善患者治疗结果至关重要.

研究的目的:

为了回顾评估结合R-GDP (rituximab,gemcitabine,dexamethasone,cisplatin) 的selinexor的疗效和安全性,作为R/R DLBCL的二线治疗.
评估后续疗法的影响,包括自身干细胞移植 (ASCT) 和CAR-T细胞疗法,对生存结果.
在这种治疗方案的背景下,分析复发性和初级耐药性疾病之间的生存差异.

主要方法:

在丹大学上海癌症中心对22名R/R DLBCL患者的回顾性分析.
患者接受了3个循环的selinexor加R-GDP,随后进行ASCT,CAR-T治疗或其他替代方案.
评估整体反应率 (ORR),整体生存率 (OS) 和无进展生存率 (PFS),以及安全性评估.

主要成果:

塞林尼克索加R-GDP疗法实现了52.4%的ORR.
平均生存期为26.9个月,1年和2年的生存率分别为67.6%和52.3%.
与其他疗法相比,通过ASCT或CAR-T疗法桥接的患者表现出明显更长的OS和PFS. 复发性疾病也显示PFS比初级耐火性疾病更长.

结论:

与R-GDP结合的Selinexor显示出作为R/R DLBCL的二线治疗方法的适度疗效.
随后的治疗选择,特别是通往ASCT或CAR-T的桥梁,对于改善存活率至关重要.
该疗程通常可以通过支持性护理进行管理,但需要进一步研究最佳测序.

关键词:

ASCT ASCT是指一个指标.在CART-T中,使用CART-T.在R-GDP中.这就是Selinexor.扩散型大B细胞淋巴瘤 (DLBCL)复发/耐火性复发/耐火性

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...